AstraZeneca Researching antibodies to target COVID-197 May 2020 03:32
The process of discovering an antibody-based treatment
AstraZeneca scientists are exploring three potential sources for antibodies against the SARS CoV-2 virus – patients who have recovered from COVID-19, immunised humanised mice and laboratory techniques such as phage display.
The spike protein on the SARS-CoV-2 virus is the primary target being explored for potential COVID-19 monoclonal antibodies. The aim is that by targeting the spike protein, the antibody will be able to neutralise the SARS-CoV-2 virus and affect its capacity to infect healthy cells.
AstraZeneca is harnessing its proprietary immune replica technology, developed as part of the abovementioned agreement with DARPA, which can capture and screen antibodies from millions of primary B cells. The company is also utilising hybridoma technology, which is a method for producing large numbers of monoclonal antibodies through a culture of hybrid cells that results from the fusion of B cells and immortal myeloma cells.
do you think they use immunised humanised mice for Research from hemo ?